The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Brugada syndrome is a genetic condition resulting in an abnormal electrical activity within the heart, which in turn increases the risk of sudden cardiac death.
The global Brugada Syndrome market was valued at US$ 1142 million in 2023 and is anticipated to reach US$ 2102.6 million by 2030, witnessing a CAGR of 8.0% during the forecast period 2024-2030.
North American market for Brugada Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Brugada Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Brugada Syndrome in Adult is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Brugada Syndrome include GeneDx, PGxHealth, GE Healthcare, Pfizer, Abbott, Medtronic, Boston Scientific and GlaxoSmithKline, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Brugada Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Brugada Syndrome.
Report Scope
The Brugada Syndrome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Brugada Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Brugada Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- GeneDx
- PGxHealth
- GE Healthcare
- Pfizer
- Abbott
- Medtronic
- Boston Scientific
- GlaxoSmithKline
Segment by Type
- Diagnosis
- Treatment
Segment by Application
- Adult
- Child
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Brugada Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Brugada Syndrome Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Diagnosis
1.2.3 Treatment
1.3 Market by Application
1.3.1 Global Brugada Syndrome Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Adult
1.3.3 Child
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Brugada Syndrome Market Perspective (2019-2030)
2.2 Brugada Syndrome Growth Trends by Region
2.2.1 Global Brugada Syndrome Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Brugada Syndrome Historic Market Size by Region (2019-2024)
2.2.3 Brugada Syndrome Forecasted Market Size by Region (2025-2030)
2.3 Brugada Syndrome Market Dynamics
2.3.1 Brugada Syndrome Industry Trends
2.3.2 Brugada Syndrome Market Drivers
2.3.3 Brugada Syndrome Market Challenges
2.3.4 Brugada Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Brugada Syndrome Players by Revenue
3.1.1 Global Top Brugada Syndrome Players by Revenue (2019-2024)
3.1.2 Global Brugada Syndrome Revenue Market Share by Players (2019-2024)
3.2 Global Brugada Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Brugada Syndrome Revenue
3.4 Global Brugada Syndrome Market Concentration Ratio
3.4.1 Global Brugada Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Brugada Syndrome Revenue in 2023
3.5 Brugada Syndrome Key Players Head office and Area Served
3.6 Key Players Brugada Syndrome Product Solution and Service
3.7 Date of Enter into Brugada Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Brugada Syndrome Breakdown Data by Type
4.1 Global Brugada Syndrome Historic Market Size by Type (2019-2024)
4.2 Global Brugada Syndrome Forecasted Market Size by Type (2025-2030)
5 Brugada Syndrome Breakdown Data by Application
5.1 Global Brugada Syndrome Historic Market Size by Application (2019-2024)
5.2 Global Brugada Syndrome Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Brugada Syndrome Market Size (2019-2030)
6.2 North America Brugada Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Brugada Syndrome Market Size by Country (2019-2024)
6.4 North America Brugada Syndrome Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Brugada Syndrome Market Size (2019-2030)
7.2 Europe Brugada Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Brugada Syndrome Market Size by Country (2019-2024)
7.4 Europe Brugada Syndrome Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Brugada Syndrome Market Size (2019-2030)
8.2 Asia-Pacific Brugada Syndrome Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Brugada Syndrome Market Size by Region (2019-2024)
8.4 Asia-Pacific Brugada Syndrome Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Brugada Syndrome Market Size (2019-2030)
9.2 Latin America Brugada Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Brugada Syndrome Market Size by Country (2019-2024)
9.4 Latin America Brugada Syndrome Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Brugada Syndrome Market Size (2019-2030)
10.2 Middle East & Africa Brugada Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Brugada Syndrome Market Size by Country (2019-2024)
10.4 Middle East & Africa Brugada Syndrome Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GeneDx
11.1.1 GeneDx Company Detail
11.1.2 GeneDx Business Overview
11.1.3 GeneDx Brugada Syndrome Introduction
11.1.4 GeneDx Revenue in Brugada Syndrome Business (2019-2024)
11.1.5 GeneDx Recent Development
11.2 PGxHealth
11.2.1 PGxHealth Company Detail
11.2.2 PGxHealth Business Overview
11.2.3 PGxHealth Brugada Syndrome Introduction
11.2.4 PGxHealth Revenue in Brugada Syndrome Business (2019-2024)
11.2.5 PGxHealth Recent Development
11.3 GE Healthcare
11.3.1 GE Healthcare Company Detail
11.3.2 GE Healthcare Business Overview
11.3.3 GE Healthcare Brugada Syndrome Introduction
11.3.4 GE Healthcare Revenue in Brugada Syndrome Business (2019-2024)
11.3.5 GE Healthcare Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Brugada Syndrome Introduction
11.4.4 Pfizer Revenue in Brugada Syndrome Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Abbott
11.5.1 Abbott Company Detail
11.5.2 Abbott Business Overview
11.5.3 Abbott Brugada Syndrome Introduction
11.5.4 Abbott Revenue in Brugada Syndrome Business (2019-2024)
11.5.5 Abbott Recent Development
11.6 Medtronic
11.6.1 Medtronic Company Detail
11.6.2 Medtronic Business Overview
11.6.3 Medtronic Brugada Syndrome Introduction
11.6.4 Medtronic Revenue in Brugada Syndrome Business (2019-2024)
11.6.5 Medtronic Recent Development
11.7 Boston Scientific
11.7.1 Boston Scientific Company Detail
11.7.2 Boston Scientific Business Overview
11.7.3 Boston Scientific Brugada Syndrome Introduction
11.7.4 Boston Scientific Revenue in Brugada Syndrome Business (2019-2024)
11.7.5 Boston Scientific Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Detail
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Brugada Syndrome Introduction
11.8.4 GlaxoSmithKline Revenue in Brugada Syndrome Business (2019-2024)
11.8.5 GlaxoSmithKline Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
